Vyluma

Vyluma is a clinical-stage biotech founded in 2020, headquartered in Bridgewater, New Jersey. Its lead candidate, NVK002, is a low-dose atropine eye drop in late-stage development to slow the progression of pediatric myopia, positioning it to potentially be the first FDA-approved pharmaceutical treatment for this condition. The company has a broader pipeline targeting other prevalent vision disorders like presbyopia and night vision disturbance, leveraging its expertise in topical ophthalmic formulations. Vyluma operates as a private, pre-revenue company aiming to transform the standard of care in ophthalmology.

Proprietary technology for formulating low-dose topical ophthalmic solutions, particularly focused on stable and effective eye drop formulations for conditions like myopia and presbyopia.

The pediatric myopia space is becoming competitive, with other companies investigating low-dose atropine (e.g., Eyenovia's MicroLine, several in Asia) and non-pharmacologic approaches like specialty contact lenses (MiSight). For presbyopia, Vyluma's NVK029 would compete with recently approved prescription eye drops (e.g., Vuity) and other OTC readers.